Donald Jung, Ph.D. – Clinical Pharmacology and DMPK
Dr. Donald Jung is a seasoned biotech and pharmaceutical industry leader with over 40 years of experience successfully leading and playing key roles in NCE preclinical and clinical development in multiple pharmaceutical companies as well as in academia. He is currently Vice President of Clinical Pharmacology and DMPK for Ascentawits Pharmaceuticals, Ltd and President of Pharmaceutical Research Services, a consulting firm for the pharmaceutical industry. He has participated in successful U.S. and ex-U.S. IND submissions as well as in NDAs (Cardene®, Cardene SR®, Toradol®, Cytovene®, Naprelan®, Naprosyn-EC®, Colazal®, Xifaxan®, Duexis®, Pyramax®, Korlym®), ANDAs (naproxen, norethindrone/ethinyl estradiol) and an over-the-counter product (Aleve®). Dr. Jung has led clinical pharmacology, toxicology and DMPK programs in multiple therapeutic indications in small- and mid-sized pharmaceutical companies including Syntex/Roche and Threshold. Prior to working in the pharmaceutical industry, he was an assistant professor of Pharmacy/Pharmacodynamics for over 6 years at the College of Pharmacy, University of Illinois, Chicago. In 1998, he founded Microconstants, an international GLP-compliant Contract Research Organization, with offices in San Diego and Beijing, focused on performing regulated bioanalysis, drug metabolism and pharmacokinetic analysis in support of discovery, preclinical and clinical drug development studies.
Dr. Jung received his Ph.D. in Pharmaceutical Sciences from the University of Arizona, Tucson, a M.S. in Pharmaceutical Chemistry at the University of California, San Francisco and a B.S. in Biochemistry from the University of California, Davis. He has authored over 100 peer-reviewed publications, served as a reviewer to multiple journals, and is an inventor on 5 issued patents.